Resumen

El propósito de este estudio es comparar la eficacia de zipalertinib combinado con quimioterapia adyuvante frente a placebo combinado con quimioterapia adyuvante en participantes con cáncer de pulmón no microcítico (CPNM) en estadio temprano (estadio IB-IIIA) resecado que presentan mutaciones poco frecuentes del receptor del factor de crecimiento epidérmico (EGFRmt).

Descripción detallada

Este estudio evaluará zipalertinib, un nuevo inhibidor de la tirosina quinasa (ITQ) del EGFR en combinación con quimioterapia adyuvante estándar basada en platino frente a placebo en combinación con quimioterapia en participantes con CPNM en estadio IB-IIIA resecado que presentan EGFRmt poco frecuentes. Aproximadamente 360 participantes serán aleatorizados 1:1 a: Brazo A: Quimioterapia basada en platino (cisplatino o carboplatino más pemetrexed) en combinación con zipalertinib 100 miligramos (mg) dos veces al día (BID), seguida de zipalertinib 100 mg BID en monoterapia, O Brazo B: Quimioterapia basada en platino (cisplatino o carboplatino más pemetrexed) en combinación con placebo BID, seguida de placebo BID en monoterapia. La duración de 1 ciclo de tratamiento será de 21 días. Se establecerá un comité independiente de monitoreo de datos (CIMD) para supervisar los datos de seguridad interinos.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

Histologically confirmed diagnosis of primary NSCLC on predominantly non-squamous histology.
Documented EGFRmt status as determined by local testing performed at a clinical laboratory improvement amendment (CLIA) certified (United States \[US\]) or accredited (outside of the US) local laboratory, defined as either one of the following EGFRmt:
exon20 insertion mutations (ex20ins) or
other uncommon, non-ex20ins EGFRmt (eg, G719X, L861Q, or S768I)
Magnetic resonance imaging (MRI) or computed tomography (CT) scan of the brain done prior to surgery. Participants in whom this was not done prior to surgery may still be enrolled if appropriate imaging (i.e., MRI or CT of the brain) is performed prior to randomization.
Complete surgical resection of the primary NSCLC is mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumor. Resection may be accomplished by open thoracotomy or video associated thoracic surgery (VATS) techniques.
Classified post-operatively as either Stage IB, IIA, IIB, or IIIA according to the tumor nodes metastasis (TNM) staging system for lung cancer (American Joint Committee on Cancer \[AJCC\] 9th edition).
Complete recovery from surgery at the time of randomization.
Eastern cooperative oncology group performance status (ECOG PS) of 0 or 1.
Archival tumor tissue available for submission, with minimum quantity sufficient to evaluate EGFRmt status and, where possible, other biomarkers.

Criterios de exclusión

Is currently receiving an investigational drug in a clinical trial or participating in any other type of medical research judged not to be scientifically or medically compatible with this study.
Treatment with any of the following within the time frame specified:
Zipalertinib (TAS6417/CLN-081) or any other EGFR inhibitor at any time.
Pre-operative or post-operative or planned radiation therapy for the current lung cancer.
Any prior systemic anticancer therapy (e.g., neoadjuvant chemotherapy), including investigational therapy, for treatment of NSCLC.
Major surgery (including primary tumor surgery, excluding placement of vascular access) within 4 weeks of the first dose of study treatment.
All prescribed medication, over-the-counter medication, vitamin preparations and other food supplements, or herbal medications that are strong or moderate cytochrome p450 (CYP) 3A4 inducers or inhibitors within 7 days prior to first dose.
Treatment with an investigational drug within five half-lives of the compound or any of its related material, if known.
Has received only segmentectomies or wedge resections.
Past medical history of interstitial lung disease (ILD)/pneumonitis, drug-induced ILD/pneumonitis or any evidence of clinically active ILD/pneumonitis.
Impaired cardiac function or clinically significant cardiac disease.
Unable to swallow tablets or has any disease or condition that may significantly affect gastrointestinal (GI) absorption of zipalertinib (such as inflammatory bowel disease, malabsorption syndrome, or prior significant bowel resection).
Participants with a history of any other cancer, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, other cancers curatively treated with no evidence of disease for \>5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) that is unstable or not controlled with treatment. Screening not required.
Active bleeding disorders.
Known:
a. Hypersensitivity: i. To the ingredients in zipalertinib/placebo or any drugs similar in structure or class. ii. To platinum-containing drugs (i.e., cisplatin, carboplatin), pemetrexed, or any known excipients of these drugs. b. Contraindications to platinum-containing drugs (i.e., cisplatin, carboplatin) or pemetrexed according to the respective local labels.
Is unable or unwilling to take dexamethasone, folic acid, and/or vitamin B12 supplementation during treatment with pemetrexed.

Ubicaciones

Instituto Argentino de Diagnóstico y Tratamiento

Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

NOT_YET_RECRUITING

Centro de Investigación Pergamino SA

Pergamino, Buenos Aires, Argentina

NOT_YET_RECRUITING

Hospital Universitario Austral

Pilar, Buenos Aires, Argentina

NOT_YET_RECRUITING

CEMAIC - Centro de Especialidades Médicas Ambulatorias e Investigación Clínica

Córdoba, Argentina

NOT_YET_RECRUITING

Un Estudio Aleatorizado, Doble Ciego, Controlado con Placebo de Fase 3 para Evaluar Zipalertinib más Quimioterapia Adyuvante frente a Placebo más Quimioterapia Adyuvante en Pacientes con CPNM en Estadio IB-IIIA con Mutaciones Poco Frecuentes de EGFR tras Resección Tumoral Completa (REZILIENT4)

Resumen

Descripción detallada

Elegibilidad

Criterios de inclusión

Criterios de exclusión

Intervenciones

Cisplatin

Carboplatin

Pemetrexed

TAS6417

Zipalertinib Matching-placebo

Ubicaciones

Instituto Argentino de Diagnóstico y Tratamiento

Centro de Investigación Pergamino SA

Hospital Universitario Austral

CEMAIC - Centro de Especialidades Médicas Ambulatorias e Investigación Clínica

Patrocinadores

Contactos

Taiho Oncology INC